BCR and chronic myelogenous leukemia, BCR-ABL1 positive: These results prove that off-target effects of imatinib do not play a key role, while inhibition of BCR-ABL1 signaling by TKIs is essential for the strong synergistic effect of the drug combination in CML cells.